Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans

• DOI: 10.1210/en.2017-00339
• Publication Date: 2017-10-05T18:09:19Z
• Authors: Mayu Kyohara; Jun Shirakawa; Tomoko Okuyama; Ayuko Kimura; Yu Togashi; Kazuki Tajima; Hisashi Hirano; Yasuo Terauchi
• Keywords: Blood Glucose; Male; Mice, Knockout; Proteomics; 0301 basic medicine; Proteome; Enzyme-Linked Immunosorbent Assay; Liraglutide; Lipids; 3. Good health; ErbB Receptors; Mice, Inbred C57BL; 03 medical and health sciences; Diabetes Mellitus, Type 2; Animals; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Biomarkers

To identify circulating factors as candidates involved in type 2 diabetes mellitus (T2DM), we conducted two different quantitative proteomic analyses: (1) db/db mouse sera were compared with db/+ obtained at 4, 8, 12, and 24 weeks of age, (2) from animals treated liraglutide without treatment. Twenty proteins differentially expressed the first experiment eight after treatment second experiment. Soluble epidermal growth factor receptor (sEGFR) was identified a common factor, its protein level significantly affected both experiments. An enzyme-linked immunosorbent assay confirmed that relatively low serum sEGFR levels mice restored by The elevated diabetic impaired insulin secretion decreased high-fat diet-fed ob/ob mice. increased administration dual inhibitor IGF-1/insulin or streptozotocin. In humans normal glucose tolerance T2DM, correlated fasting blood glucose, insulin, homeostatic model assessment resistance, HbA1c, total cholesterol, low-density lipoprotein triglycerides levels. These findings suggest might be biomarker for evaluating resistance therapeutic target liraglutide.